BioStock: Chordate Medical notified on when to resume migraine study
Chordate Medical’s treatment method is currently being evaluated in a migraine study, but due to the pandemic, it has been paused for a fairly long time. Now, however, the company has been notified that the study can be resumed in March after the healthcare professionals at the study clinics in Finland have been vaccinated against Covid-19. The plan is now to recruit the last patient in the study in March, which means that Chordate Medical hopefully will complete the migraine study in July.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se